Treats heartburn and other symptoms associated GERD. ANDA 205606, held by Aurobindo Pharma Ltd. Esomeprazole Magnesium.
As of Nov 16, 2026, ANDA 205606 (Esomeprazole Magnesium), held by Aurobindo Pharma Ltd, was first approved by FDA on Apr 21, 2016, with 8 approved supplements and 0 published complete response letters.
Esomeprazole magnesium delayed-release capsules are a proton pump inhibitor (PPI). Esomeprazole magnesium delayed-release capsules are indicated for the: Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. Maintenance of healing of EE in adults. Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 21, 2016 | Original application | Approved | None posted |
| Esomeprazole MagnesiumEQ 20MG BASE · capsule, delayed rel pellets;oral | Esomeprazole Magnesium | Rx |
| Esomeprazole MagnesiumEQ 40MG BASE · capsule, delayed rel pellets;oral | Esomeprazole Magnesium | Rx |
| May 13, 2024 | Supplement 4Labeling · Standard review | Approved | None posted |
| May 13, 2024 | Supplement 6Labeling · Standard review | Approved | None posted |
| May 13, 2024 | Supplement 8Labeling · Standard review | Approved | None posted |
| May 13, 2024 | Supplement 14Labeling · Standard review | Approved | None posted |
| May 13, 2024 | Supplement 17Labeling · Standard review | Approved | None posted |
| May 13, 2024 | Supplement 19Labeling · Standard review | Approved | None posted |
| May 13, 2024 | Supplement 21Labeling · Standard review | Approved | None posted |
| Nov 20, 2023 | Supplement 16Manufacturing | Approved | None posted |
| Apr 21, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters